KCP-330-020
-
- STATUS
- Recruiting
-
- participants needed
- 6
Summary
The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each 42 day cycle until disease progression, intolerability, consent withdrawal or unblinding in Phase 2, 3, and open-label portion of the study.
Description
A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
Details
| Condition | Liposarcoma |
|---|---|
| Age | 18years - 99years |
| Clinical Study Identifier | 02606461 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.